The DOI matches its Crossref record.
Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial
Open accessAbstract
Summary Background Benzodiazepine-refractory, or established, status epilepticus is thought to be of similar pathophysiology in children and adults, but differences in underlying aetiology and pharmacodynamics might differentially affect response to therapy. In the Established Status Epilepticus Treatment Trial (ESETT) we compared the efficacy and safety of levetiracetam, fosphenytoin, and valproate in established status epilepticus, and here we describe our results after extending enrolment in children to compare outcomes in three age groups. Methods In this multicentre, double-blind, response-adaptive, randomised controlled trial, we recruited patients from 58 hospital emergency departments across the USA. Patients were eligible for inclusion if they were aged 2 years or older, had been treated for a generalised convulsive seizure of longer than 5 min duration with adequate doses of benzodiazepines, and continued to have persistent or recurrent convulsions in the emergency department for at least 5 min and no more than 30 min after the last dose of benzodiazepine. Patients were randomly assigned in a response-adaptive manner, using Bayesian methods and stratified by age group (<18 years, 18–65 years, and >65 years), to levetiracetam, fosphenytoin, or valproate. All patients, investigators, study staff, and pharmacists were masked to treatment allocation. The primary outcome was absence of clinically apparent seizures with improved consciousness and without additional antiseizure medication at 1 h from start of drug infusion. The primary safety outcome was life-threatening hypotension or cardiac arrhythmia. The efficacy and safety outcomes were analysed by intention to treat. This study is registered in ClinicalTrials.gov, NCT01960075. Findings Between Nov 3, 2015, and Dec 29, 2018, we enrolled 478 patients and 462 unique patients were included: 225 children (aged <18 years), 186 adults (18–65 years), and 51 older adults (>65 years). 175 (38%) patients were randomly assigned to levetiracetam, 142 (31%) to fosphenyltoin, and 145 (31%) were to valproate. Baseline characteristics were balanced across treatments within age groups. The primary efficacy outcome was met in those treated with levetiracetam for 52% (95% credible interval 41–62) of children, 44% (33–55) of adults, and 37% (19–59) of older adults; with fosphenytoin in 49% (38–61) of children, 46% (34–59) of adults, and 35% (17–59) of older adults; and with valproate in 52% (41–63) of children, 46% (34–58) of adults, and 47% (25–70) of older adults. No differences were detected in efficacy or primary safety outcome by drug within each age group. With the exception of endotracheal intubation in children, secondary safety outcomes did not significantly differ by drug within each age group. Interpretation Children, adults, and older adults with established status epilepticus respond similarly to levetiracetam, fosphenytoin, and valproate, with treatment success in approximately half of patients. Any of the three drugs can be considered as a potential first-choice, second-line drug for benzodiazepine-refractory status epilepticus.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus
Kapur, J., Elm, J., Chamberlain, J. M., Barsan, W., Cloyd, J., Lowenstein, D., Shinnar, S., Conwit, R., Meinzer, C., Cock, H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1905795 · Cited by 551
Self-citationEuropean Resuscitation Council Guidelines 2021: Paediatric Life Support
Van de Voorde, P., Turner, N. M., Djakow, J., de Lucas, N., Martinez-Mejias, A., Biarent, D., Bingham, R., Brissaud, O., Hoffmann, F., Johannesdottir, G. B., et al. (2021) · Resuscitation · doi:10.1016/j.resuscitation.2021.02.015 · Cited by 448
Löscher, W., & Klein, P. (2021) · CNS Drugs · doi:10.1007/s40263-021-00827-8 · Cited by 367
National UK programme of community health workers for COVID-19 response
Haines, A., de Barros, E. F., Berlin, A., Heymann, D. L., & Harris, M. J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30735-2 · Cited by 237
Presynaptic antiseizure medications-basic mechanisms and clues for their rational combinations
Czapińska-Ciepiela, E. K., Łuszczki, J., Czapiński, P., Czuczwar, S. J., & Lasoń, W. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00603-7 · Cited by 13
Metadata
- Authors
- Chamberlain, J. M., Kapur, J., Shinnar, S., Elm, J., Holsti, M., Babcock, L., Rogers, A., Barsan, W., Cloyd, J., Lowenstein, D., Bleck, T. P., Conwit, R., Meinzer, C., Cock, H., Fountain, N. B., Underwood, E., Connor, J. T., Silbergleit, R., Gray, E., Gunter, S., Fansler, A., Stevenson, V., Bengelink, E., Harney, D., Speers, M., Black, J., Fisher, N., Harsh, D., Ramakrishnan, A., Harris, L., Bozeman, N., Spiteri, A., Palesch, Y., Tillman, H., Zhao, W., Pauls, Q., Arnaud, C., Dillon, C. R., Riley, J., Alford, T., Conner, C., Coles, L., Sathe, A., Janis, S., Hartman, A., Fureman, B., Trinka, E., Treiman, D., Wright, D., Ratcliff, J., Hall, A., Williams, A., Simon, H., Stanley, N., Humphries, R., Mims, T., Short, J., Jones, E., Ottman, M., Gentile, N., Isenberg, D., Reimer, H., Sayoc Kalugdan, V., Hemphill, C., Yi Madhok, D., Duncan, J., Randazzo, D., Quinn, J., Visweswaran, A., Mann, R., Adeoye, O., McMullan, J., Foreman, B., Keegan, S., Biros, M., Driver, B., Hendrickson, A., Stang, J., Lewandowski, C., Miller, J., Chaudhry, K., Berry, S., Warden, C., Blake, R., Cook, J. N., Sabolick, E., Selman, A., Kissman, K., Moore, M., Huff, J. S., Becker, L., Claassen, J., Velazquez, A., Falo, C., Coralic, Z., Grupp-Phelan, J., Baren, J., Ellison, A., Woodford, A., Samba, I., Kittick, M., Riviello, R., Massey, J., Bonacquisti, L., Levine, S., Motov, S., Fromm, C., Hossain, R., Likourezos, A., Pushkar, I., Terndrup, T., Khaliqdina, S., Hill, M., Peterson, B., Terwilliger, A., Holm, J., Wicklund, K., Wewerka, S., Welch, R., Pearson, C., Kumar, V. A., Ayaz, F., Bhuiyan, S., Mika, V. H., Morgan, L., Jones, F., Dishman, L., Henry, T., Erickson, F., Staugaitis, A., Lawyer, C., Miller, K., Callaway, C., Urban, A., DiFiore, S., Adams, P., Baum, B., Nomura, J., Davis, B., Aufderheide, T., Emmrich, A., Mena, M., Labinski, J., Ogedegbe, C., McCarthy, D., Villot-Santiago, A., Goldstein, J., Rosenthal, E. S., Cohen, A., Mei Su, C., Tirrell, G., Howell, M., Hendrickson, M., Nerheim, D., Jaton, E., Biney, B., Gibson, C., Dahlmeier, E., Blackburn, K. (., Vaughan-Ogunlusi, O. (., Zehtabchi, S., Sinert, R., Petty, B., Warden, C., Youngquist, S., Carlson, M., Gilles, N., Weingast, S. (., Stern, B., Hopp, J., Ganley, V., Ornato, J., Hogan, C., Payne, A., Shreve, K., Dayan, P., Kuppermann, N., Denninghoff, K., Stanley, R., Ruddy, R., Lerner, E. B., Dean, J. M., Casper, C., Nigrovic, L., Schalick, W., Nelson, D., Thomas, B., Okada, P., Lee, A., Truesdale, N., Chan, S., Naresh, M., Robinson, V., Hwang, J., Carlston, K., Dela Cruz, M., Harbour, T., Karki, R., Cohen, D. M., Nowakowski, A., Lin, C., Fisher Kenny, E., Steele, D., Merck, L. H., Ryan, E., Basso, K., D'Urso, L. (., Brown, K., Nauman, G., Ledda, M., Gillen, S., Grant, V., Vance, C., Nishijima, D. K., Pimenta, K., Herzog, N., Bennett, J., Eisenhart, C., Thomas, D., Wagner, D., Hickey, R. W., Azrak, R., Rubalcava, D., Mondragon, J., Gonzalez, V., Khalil, M., Pearson, C., Kumar, V. A., Hart, K., Parker, S., Lumba-Brown, A., Quayle, K., Chinta, S., Robinson, D., Kwok, M., Peery, B., Ochs, J., & Suarez, L.
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2020-04
- Volume
- 395
- Issue
- 10231
- Pages
- 1217-1224
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W3011126394
- Cited by
- 238
- References
- 0
- FWCI
- 23.62
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial. https://app.cochat.ai/papers/10.1016/s0140-6736(20)30611-5
- The paper
- Chamberlain, J. M., Kapur, J., Shinnar, S., Elm, J., Holsti, M., Babcock, L., Rogers, A., Barsan, W., Cloyd, J., Lowenstein, D., Bleck, T. P., Conwit, R., Meinzer, C., Cock, H., Fountain, N. B., Underwood, E., Connor, J. T., Silbergleit, R., Gray, E., . . . Suarez, L. (2020). Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial. The Lancet. https://doi.org/10.1016/s0140-6736(20)30611-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.